학술논문

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Document Type
Article
Source
In: Immunotherapy Advances. (Immunotherapy Advances, 2024, 4(1))
Subject
Language
English
ISSN
27324303